Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108153 · ClinicalTrials.gov registry record · Phase 2
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
A Phase 2 study of Cystic Fibrosis (CF), sponsored by Sionna Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 13
- Study locations
NCT07108153 is a Phase 2 study of Cystic Fibrosis (CF) that is actively recruiting participants, run by Sionna Therapeutics. The registered enrollment target is 16 participants, below the 140-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (89% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT07108153, a Phase 2 study of Cystic Fibrosis (CF), is actively recruiting participants, sponsored by Sionna Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
Conditions Studied
Interventions
- DRUG SION-719
- DRUG Placebo-to-match SION-719
Study Locations (13)
New York
- New York Medical College - Hawthorne
- Columbia University - New York
Colorado
- National Jewish Health - Denver
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins - Baltimore
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Washington University - St Louis
Ohio
- University Hospital of Cleveland - Cleveland
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07108153
The ClinicalTrials.gov registry entry for NCT07108153 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (89% lower). The listed sponsor is Sionna Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which SION-719 is the first listed.
NCT07108153 reports 13 study locations spanning 12 distinct geographic areas - top geographies include New York, Colorado, Iowa.
Frequently Asked Questions
What is clinical trial NCT07108153 about?
NCT07108153 is a clinical study titled "Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
What is the current status of trial NCT07108153?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2025-11-03. Estimated completion is 2026-07.
What conditions does trial NCT07108153 study?
This clinical trial studies the following conditions: Cystic Fibrosis (CF).
What interventions are being tested in trial NCT07108153?
The interventions under investigation include: SION-719 (DRUG), Placebo-to-match SION-719 (DRUG).
Who is sponsoring clinical trial NCT07108153?
This trial is sponsored by Sionna Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108153 being conducted?
This trial has 13 study locations across Colorado, Iowa, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis (CF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study With Phage for CF Subjects With Pseudomonas Lung Infection
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
COMPLETED · Phase 2
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
RECRUITING · Phase 3
-
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.